Harvard and Deerfield establish Lab1636, a major translational research alliance - March 2019

Deerfield commits $100M to inject fuel into translational life science research at Harvard

Cambridge, Mass. – March 13, 2019 – Harvard University and Deerfield Management, a healthcare investment firm, have established a major strategic R&D alliance to speed the development and translation of biomedical and life-science innovations into transformative treatments that can improve life, health, and medical care. Through a newly launched company called Lab1636, Deerfield has committed an unprecedented $100 million in initial funding to support the alliance.

“We envision the Harvard-Deerfield collaboration as a powerful means to fuel translational research across the University, enabling promising innovations to advance beyond their laboratory roots,” said Harvard Provost Alan M. Garber.

“By working with an alliance partner who is prepared to support early-stage research and to invest in the success of pre-clinical and clinical-stage commercial development, we’re enhancing the opportunities for Harvard’s life-changing innovations to reach patients in need,” added Isaac T. Kohlberg, Senior Associate Provost and Chief Technology Development Officer at Harvard. “Success in a research alliance requires a partner with a long vision and operational and development expertise, as well as the financial resources, and we’re delighted to launch this initiative with Deerfield.”

A private company wholly owned by affiliates of Deerfield, Lab1636 will support Harvard R&D projects throughout various stages of drug discovery and development, for example enabling studies to explicate the biology of disease, validate therapeutic targets, or achieve a proof-of-concept necessary for filing an Investigational New Drug (IND) application.

“Harvard is an outstanding partner for an alliance,” said James E. Flynn, Managing Partner at Deerfield. “The University’s outstanding science, breadth of technologies, and mix of esteemed junior and senior faculty constitute a fertile environment for the continuous generation of novel insights. This, in combination with its experience advancing potential therapeutics, makes it the perfect place to establish an impactful translational partnership.”

At any research university, the most commercially promising innovations eventually outgrow the lab bench, requiring greater resources or more focused development than an academic setting can provide. In addition to funding research on campus, Lab1636 may facilitate licenses to outside companies and is equipped to provide substantial support to the launch and growth of new startups dedicated to developing Harvard technologies.

“The sheer scope of this collaboration with Deerfield may prove transformative for Harvard research,” said Vivian Berlin, Managing Director, Strategic Partnerships in OTD. “This alliance has immense potential to bridge the development gap, ensure continuity of resources, and complement our other major translational programs, such as the Blavatnik Biomedical Accelerator.”
Kohlberg added, “We hope that our R&D alliance with Deerfield will further sustain and speed the commercialization of innovations from across the University toward societal impact.”

Harvard’s R&D projects to be funded by Lab1636 will be selected by a joint advisory committee, and the projects will be initiated by principal investigators from labs across the University. The projects will generally focus on the development of novel therapeutics, ideally advancing many to a stage that would enable the filing of an IND application and, if successful, the commencement of clinical trials in patients.

About Harvard Office of Technology Development

Harvard’s Office of Technology Development (OTD) promotes the public good by fostering innovation and translating new inventions made at Harvard University into useful products that are available and beneficial to society. Our integrated approach to technology development comprises sponsored research and corporate alliances, intellectual property management, and technology commercialization through venture creation and licensing. More than 70 startups have launched to commercialize Harvard technologies in the past 5 years, collectively raising more than a billion dollars in financing. To further bridge the academic-industry development gap, Harvard OTD manages the Blavatnik Biomedical Accelerator and the Physical Sciences & Engineering Accelerator. For more information, please visit https://otd.harvard.edu.

About Deerfield Management

Deerfield is a healthcare investment management firm committed to advancing healthcare through investment, information and philanthropy.